Acetylsalicylic acid in primary prevention of cardiovascular disease

Area of Science:

• Cardiology
• Preventive Medicine
• Pharmacology

Background:

• Acetylsalicylic acid (ASA) is a cornerstone in secondary prevention of ischemic events.
• Its role in primary prevention is debated due to evolving medical practices and conflicting study outcomes.
• Older studies on ASA in primary prevention did not reflect modern preventive care standards.

Purpose of the Study:

• To review the historical development and current evidence regarding acetylsalicylic acid in primary prevention.
• To analyze recent studies and meta-analyses published in 2018 concerning ASA's primary preventive role.
• To discuss current indications and future directions for aspirin therapy in primary prevention.

Main Methods:

• Literature review of studies on acetylsalicylic acid for primary prevention.
• Analysis of recent research (2018) and meta-analyses.
• Evaluation of clinical benefits versus risks in various patient populations.

Main Results:

• Initial studies indicated reduced myocardial infarctions and ischemic strokes but no impact on overall mortality.
• Recent studies and meta-analyses have not demonstrated a significant mortality benefit.
• Clinical benefits of aspirin may outweigh risks in specific subpopulations and patient groups.

Conclusions:

• The efficacy of aspirin in primary prevention requires careful consideration of individual patient risk factors.
• While not universally recommended for primary prevention due to lack of mortality benefit, aspirin may be beneficial for select individuals.
• Further research is needed to refine guidelines for aspirin use in primary prevention.